Piramal Pharma Other Announcement
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.
Piramal Pharma Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.
Piramal Pharma submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms adherence to SEBI regulations with no adverse observations noted.
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel (KMP) under SEBI Regulation 30(5). CFO Vivek Valsaraj and Company Secretary Maneesh Sharma are authorized for determining materiality and making stock exchange disclosures.
Piramal Pharma Ltd received an improved ESG rating of '64' from NSE Sustainability for FY 2024-25, up from the previous score of 61. The voluntary rating reflects the company's progress in sustainability and responsible operations based on public disclosures.